Ramipril
- Generic Name
- Ramipril
- Brand Names
- Altace, Altace HCT
- Drug Type
- Small Molecule
- Chemical Formula
- C23H32N2O5
- CAS Number
- 87333-19-5
- Unique Ingredient Identifier
- L35JN3I7SJ
- Background
Ramipril is a prodrug belonging to the angiotensin-converting enzyme (ACE) inhibitor class of medications. It is metabolized to ramiprilat in the liver and, to a lesser extent, kidneys. Ramiprilat is a potent, competitive inhibitor of ACE, the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure...
- Indication
For the management of mild to severe hypertension. May be used to reduce cardiovascular mortality following myocardial infarction in hemodynamically stable individuals who develop clinical signs of congestive heart failure within a few days following myocardial infarction. To reduce the rate of death, myocardial infarction and stroke in individuals at high ...
- Associated Conditions
- Cardiovascular Events, Diabetic Nephropathy, Heart Failure, Hearth Failure With Reduced Ejection Fraction (HFrEF), Hypertension, Myocardial Infarction, Nondiabetic proteinuric chronic kidney disease, Stroke, High risk cardiovascular event
- Associated Therapies
- -
The Study of Atherosclerosis With Ramipril and Rosiglitazone
- Conditions
- First Posted Date
- 2005-09-01
- Last Posted Date
- 2008-08-25
- Lead Sponsor
- Gerstein, Hertzel, MD
- Target Recruit Count
- 1200
- Registration Number
- NCT00140647
The DREAM (Diabetes Reduction Assessment With Ramipril and Rosiglitazone Medication) Trial
- Conditions
- First Posted Date
- 2004-11-08
- Last Posted Date
- 2009-11-10
- Lead Sponsor
- Gerstein, Hertzel, MD
- Target Recruit Count
- 5000
- Registration Number
- NCT00095654
Prevention of Atherosclerosis and Heart Disease in Patients With Systemic Lupus Erythematosis (SLE)
- Conditions
- First Posted Date
- 2003-02-14
- Last Posted Date
- 2013-12-24
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 150
- Registration Number
- NCT00054938
- Locations
- 🇺🇸
Brigham and Women's Hospital, RBB Brigham Arthritis Center, Boston, Massachusetts, United States
Treatment of Pediatric Hypertension With Altace Trial
- Conditions
- First Posted Date
- 2002-08-26
- Last Posted Date
- 2012-06-07
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 310
- Registration Number
- NCT00044265
- Locations
- 🇺🇸
Hershey Medical Center, Hershey, Pennsylvania, United States
🇺🇸PCTI at Columbus Children's Hospital, Columbus, Ohio, United States
🇺🇸The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
Effects of Angiotensin-Converting Enzyme Inhibitor (Ramipril) Therapy on Blood Vessel Inflammation
- Conditions
- First Posted Date
- 2000-06-29
- Last Posted Date
- 2008-03-04
- Target Recruit Count
- 25
- Registration Number
- NCT00005928
- Locations
- 🇺🇸
National Heart, Lung and Blood Institute (NHLBI), Bethesda, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.